Humanitarian Device Exemptions: When a Narrow Authorization Becomes a Sales Strategy

Medical device humanitarian exemption fraud can arise when a manufacturer misrepresents a device’s limited FDA authorization and causes false claims for government payment. The authorization, the sales pitch and the hospital’s bill can tell different stories about the same implant. For someone inside regulatory affairs, sales or hospital billing, the important connection is what the company said the device could do, how that message reached the clinical decision, and what the government paid for.

What Is a Humanitarian Device Exemption?

A humanitarian device exemption allows FDA to approve a device for a small patient population without requiring the ordinary showing of effectiveness. The pathway retains conditions about risk, probable benefit, available alternatives, price and institutional oversight.

The purpose is to encourage devices for patients with uncommon diseases or conditions. FDA must find that the device would not otherwise be available through the ordinary approval route and that no comparable device is available. It must also find that the device will not expose patients to unreasonable or significant risk, and that its probable health benefit outweighs the risk of injury or illness.

A sales pitch that presents probable benefit as FDA proof of effectiveness gives the surgeon a finding the agency did not make. A regulatory employee may know exactly which finding supported approval. The surgeon hearing a presentation needs the same distinction to survive the trip from the approval file to the sales material.

OP-1 and the Mixing Instructions

The 2009 criminal indictment charged that Stryker Biotech promoted combinations of OP-1 products with Calstrux, a bone void filler, and supplied mixing instructions to surgeons, medical technicians and others. The government alleged that some instructions called for the combined product to be molded into shapes resembling cigars and small sausages.

The products, OP-1 Implant and OP-1 Putty, had FDA approval under the restrictive humanitarian pathway. The government’s account described both a small-population condition and a prohibition on selling for profit. In the indictment’s account, an approval for a limited patient population had become a sales pitch with instructions for mixing products into new shapes.

The indictment also charged the company and its former president with false statements about how many patients the company treated annually with OP-1 Putty.

Stryker Corporation’s annual report filed in February 2012 described a resolution involving a corporate misdemeanor and reported that the Justice Department dismissed all felony charges against Stryker Biotech. It also reported dismissal of all charges against the current and former employees. The mixing and patient-count allegations remain the indictment’s account of the conduct.

The Population Rule Has Changed

The statute now covers diseases or conditions affecting not more than 8,000 people in the United States. The older rule described in the 2009 Stryker Biotech indictment concerned conditions affecting fewer than 4,000 patients. The rule attached to the period matters when examining an older sales program.

Can an HDE Device Be Sold for a Profit?

Some devices with a humanitarian device exemption can qualify for a profit exception. The general rule limits the selling amount to the costs of research and development, fabrication and distribution. The statute provides exceptions for qualifying pediatric devices and certain devices for conditions that do not occur in pediatric patients, subject to an Annual Distribution Number set by the government.

The statute gives October 1, 2027 as the deadline for new profit-exemption requests. The exception and the annual distribution limit belong beside the device’s approval history when examining its commercial records.

The cost ceiling makes the manufacturer’s accounting part of the approval story. A finance employee may understand the cost calculation while a regulatory colleague holds the approval on which the pricing decision depends.

We connect the company’s pricing and authorization records to the hospital’s purchase, the use of the device and the eventual claim. That is how a concern about the sales program becomes a question about government money.

What Does the Institutional Review Board Approve?

The humanitarian-device statute requires approval of the use before the device is used, through an institutional review committee or an appropriate local committee. It also requires a facility where an institutional review committee supervises clinical testing of devices. The statute makes an emergency exception when waiting for approval would risk serious harm or death.

The hospital’s committee file may show the use presented for approval, while the clinical record shows what happened. If the concern is that sales instructions expanded the use, we examine what the institution approved alongside what those instructions asked clinicians to do.

When the Sales Message Reaches a Government Claim

A manufacturer can cause a false claim through health care providers that use its product. The connection runs from the manufacturer’s representation to the surgeon’s or hospital’s decision, then to the information supporting payment. The manufacturer may influence the purchase even though the hospital submits the bill.

The commercial structure explains why. HHS-OIG’s analysis of implant selection describes how physicians may make or strongly influence both the brand and type of implant. The hospital buys the product. A sales message aimed at the surgeon can reach the purchasing decision through the person who chooses what goes into the patient.

A manufacturer’s clinical specialist can also be present at the procedure itself. The American College of Surgeons’ 2016 guidance on industry representatives in the operating room describes the representative as an educator and facilitator, present at the surgeon’s discretion. It says representatives should not make medical decisions, perform surgery or have direct patient contact.

For a humanitarian device exemption inquiry, we compare what the representative explained with the authorized product and the institutional approval. A specialist who heard the explanation may know how a training document translated into instructions at the procedure.

In documented consignment arrangements, the manufacturer retains ownership of the product until use or implantation, when the sale occurs. That makes shipment records and patient-use records different measures when examining the company’s account of where a device went.

The 2020 paper A Forensic Accountant’s Guide to the Most Potent Federal Laws Used Against Healthcare Fraud, in the Journal of Forensic and Investigative Accounting explains how false claims can involve services actually delivered, with false representations about compliance or misleading omissions in the information supporting payment. For a humanitarian device exemption inquiry, that directs attention to what the provider represented about the treatment and what the manufacturer supplied to support it.

How Does Reimbursement Work for Medical Devices?

Medicare generally pays for an implanted device within payment for the procedure or hospital stay. Humanitarian device exemption approval addresses whether the device can be marketed. The treatment and the payer’s requirements determine the coverage question.

The Medicare coverage law requires covered items and services to be reasonable and necessary for diagnosis or treatment.

A hospital may report a device code and charge even when the device receives no separate payment. We follow the sales representation through the treatment record and the claim to see what the provider asked the government to pay for.

What Evidence Is Needed to Prove Fraud?

The strongest evidence connects the company’s representation, the device’s authorized use, the treatment and the government claim. It also shows what the people responsible knew.

Regulatory, sales, finance and hospital staff may each hold part of that connection, from the approval and field instructions to the cost calculation and billing records. We work through those records with you to establish how the company’s message affected the clinical and payment decisions.

A whistleblower or qui tam case under the False Claims Act can pay 15% to 30% of what the government recovers.

When the Approval and the Sales Instructions Diverge

If you know the humanitarian approval file and the instructions reaching surgeons tell different stories, talk to our whistleblower experts about the device and the sales program. We connect the authorization, the clinical decisions and the government claims, and bring in medical device fraud whistleblower lawyers who understand promotion and reimbursement. We stay beside you through the whole process to build your strongest medical device whistleblower case.